ArticleFrontiers in pharmacology2018
Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Unveiling the Link Between Inflammation and Adaptive Immunity in Breast Cancer.Frontiers in immunology · 2019Pooled it
- Advances in high-throughput drug screening based on pharmacotranscriptomics.Journal of advanced research · 2026Review
- Enhanced drug-disease association prediction through representation learning on similarity networks.Biology methods & protocols · 2026Article
- Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.International journal of molecular sciences · 2025Article
- Redefining Breast Cancer Care by Harnessing Computational Drug Repositioning.Medicina (Kaunas, Lithuania) · 2025Review
- Improving computational drug repositioning through multi-source disease similarity networks.Scientific reports · 2025Article
- Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches.Proteomics · 2025Article
- Potential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors.International journal of molecular sciences · 2024Article
- Identifying patterns to uncover the importance of biological pathways on known drug repurposing scenarios.BMC genomics · 2024Article
- Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.European journal of medical research · 2023Review
- Evaluation of the Possible Pathways Involved in the Protective Effects of Quercetin, Naringenin, and Rutin at the Gene, Protein and miRNA Levels Using In-Silico Multidimensional Data Analysis.Molecules (Basel, Switzerland) · 2023Article
- Informatics on Drug Repurposing for Breast Cancer.Drug design, development and therapy · 2023Review
- Article
- Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation.Frontiers in pharmacology · 2022Article
- Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer.Cancers · 2021Article
- Review
- Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis.Cell reports methods · 2021Article
- Highly connected, non-redundant microRNA functional control in breast cancer molecular subtypes.Interface focus · 2021Article
- An Information Theoretical Multilayer Network Approach to Breast Cancer Transcriptional Regulation.Frontiers in genetics · 2021Article
- Drug repurposing for breast cancer therapy: Old weapon for new battle.Seminars in cancer biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a major public health problem which treatment needs new pharmacological options. In the last decades, during the postgenomic era new theoretical and technological tools that give us novel and promising ways to address these problems have emerged. In this work, we integrate several tools that exploit disease-specific experimental transcriptomic results in addition to information from biological and pharmacological data bases obtaining a contextual prioritization of pathways and drugs in breast cancer subtypes. The usefulness of these results should be evaluated in terms of drug repurposing in each breast cancer molecular subtype therapy. In favor of breast cancer patients, this methodology could be further developed to provide personalized treatment schemes. The latter are particularly needed in those breast cancer subtypes with limited therapeutic options or those who have developed resistance to the current pharmacological schemes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.